A5086027531- Liver Disease Diagnosis and Treatment
- Hepatitis C virus research
- Hepatitis B Virus Studies
- Renal Diseases and Glomerulopathies
- Systemic Lupus Erythematosus Research
- MRI in cancer diagnosis
- Diabetes and associated disorders
- Pediatric Hepatobiliary Diseases and Treatments
- Autoimmune Neurological Disorders and Treatments
- Gallbladder and Bile Duct Disorders
- Genetic and Kidney Cyst Diseases
- Neurological and metabolic disorders
- Epilepsy research and treatment
- Peroxisome Proliferator-Activated Receptors
- Chronic Kidney Disease and Diabetes
- Cancer, Hypoxia, and Metabolism
- Eicosanoids and Hypertension Pharmacology
- Fibroblast Growth Factor Research
- Pediatric Urology and Nephrology Studies
- Renal and Vascular Pathologies
Fukui-ken Saiseikai Hospital
2015
University of Fukui
2007-2015
Urasoe General Hospital
2015
Kobe Asahi Hospital
2006-2011
Kobe Gakuin University
2008
Kobe Pharmaceutical University
2008
University of Fukui Hospital
2006
Background. Peroxisome proliferator-activated receptor (PPAR)-γ may counteract tissue fibrosis via its anti-inflammatory actions, while hypoxia, a new pro-fibrotic factor, reportedly modifies PPAR-γ expression. However, the effects of hypoxia on expression and actions have yet remained to be clarified in renal tubular cells.
Although all the mechanisms of elimination hepatitis C virus (HCV) by Interferon (IFN) have not been fully elucidated, 2'-5'-oligoadenylate (2-5A) system is one antiviral effect IFN. Consequently, measurement synthetase (2-5AS) activity could be useful for evaluation IFN treatment. This retrospective study was aimed at assessing whether 2-5AS functions as a clinical marker virological response to PEG-interferon-alpha2b (PEG-IFN) plus ribavirin therapy chronic C.The 32 patients included in...
Double-filtration plasmapheresis (DFPP) together with interferon (IFN) administration produces a substantial reduction in the viral load during early stages of treatment.Based on their responses to previous pegylated IFN and ribavirin (PEG-IFN/RBV) therapy, 20 patients were divided into null virological response (NVR; n = 12) relapse (n 8) groups. DFPP was used combination IFN-β/RBV subsequent PEG-IFN-α2a/RBV therapy (DFPP + then PEG-IFN/RBV). Early dynamics assessed, focusing especially...
Case presentation: An 88-year-old man with past medical history of choledocholithiasis, peribiliary cyst and contrast media allergy presented to our hospital fever, vomiting chill. Abdominal tenderness jaundice were absent at initial physical examination. Initial laboratory result revealed increase in white blood cells C-reactive protein but serum level hepatobiliary enzymes normal. As a choledocholithiasis was noted on CT abdomen, ERCP attempted. The patient has been discharged from after...
症例は77歳, 女性. 糖尿病性腎症による慢性腎不全であったが, 透析導入は拒否していた. しかし, 体液貯留過剰のため緊急導入となった. 週2回の維持透析にて尿毒症は改善したが, 入院時より傾眠傾向および意欲・食欲の低下を認め, 次第に増悪し, 看護への抵抗などの精神症状も出現した. 精神科にて, せん妄状態と診断された. 神経内科では, 頭部CT・MRI上は加齢に伴う脳萎縮・慢性虚血性変化を認めるのみであったが, 脳波で全般性徐波を認めたことから代謝性脳症や自己免疫性脳症の可能性が示唆された. 甲状腺機能は正常であったが, 抗甲状腺サイログロブリン (TG) 抗体が100U/mL以上と強陽性であったことより橋本脳症が疑われた. 橋本脳症で特異的な抗N末端α-エノラーゼ (NAE) 抗体が陽性であったため橋本脳症と診断され, PSL 30mgの内服が開始された. 精神神経症状は著明に改善し, 脳波も改善を認めた. 透析患者の意識障害の原因は多種に及ぶが, 橋本脳症の可能性も念頭におき, 甲状腺機能が正常であっても, 抗甲状腺抗体や抗NAE抗体を測定することが早期診断と治療に繋がると考えられた.
It is well known that combination therapy with interferon (IFN) and ribavirin may not achieve the full therapeutic effect in patients high-titers(≥100 KIU/mL) for hepatitis C virus genotype 1 b.Further,high low-density lipoprotein cholesterol (LDL-C) levels are reported to be a significant indicator of potential IFN patients,though this still controversial.In study,we examined serum various lipids - comprising LDL-C,total-cholesterol (T-Cho),triglyceride (TG) high-density (HDL-C)-before...